The Electrospinning Company expands development, licensing and manufacturing partnerships across North America following USPTO grant
OXFORD, UK – 06/10/2026 – The Electrospinning Company has been granted a U.S. patent for its Symatix® biosynthetic technology. The patent gives medical device partners protected access to the technology as the company expands its development, licensing and manufacturing partnerships across North America.
“The granting of this U.S. patent shows our team’s rigorous approach to material innovation and provides our medical device partners with robust, legally protected technology,” said Ann Kramer, CEO of The Electrospinning Company. “This ensures they can confidently design implantable materials with exceptional handling, cellular response, and fully scalable manufacturability.”
The patented Symatix® technology combines electrospun synthetic fibres with natural materials such as collagen, hyaluronic acid and chitosan. The biological materials are embedded directly within or alongside the electrospun fibre network in a precise, controlled process.
The Symatix® membrane, comprising a resorbable polymer and hyaluronic acid, was developed as an alternative to human amniotic membranes for use in corneal repair, and has demonstrated excellent performance in vitro, in vivo and in surgical handling tests.
Read the science: https://tvst.arvojournals.org/article.aspx?articleid=2793631
The Symatix® platform is applied to opportunities across skin substitutes and chronic wounds, internal soft-tissue repair, abdominal wall and hernia applications, and ocular repair.
The Electrospinning Company operates from ISO Class VII clean room facilities under ISO 13485 certification on the Harwell Innovation Campus near Oxford.
For more information about The Electrospinning Company and its Symatix® platform, visit www.electrospinning.co.uk.
About The Electrospinning Company
The Electrospinning Company designs, develops, and manufactures advanced nanofibrous biomaterials and coatings for implantable medical devices and regenerative medicine. Based on the Harwell Innovation Campus near Oxford, UK, the company supports medical device innovation from initial feasibility studies through to validated, high-volume cleanroom contract manufacturing under ISO 13485 accreditation.